Prediction of recurrence from metabolites and expression of TOP2A and EZH2 in prostate cancer patients treated with radiotherapy

The dual upregulation of TOP2A and EZH2 gene expression has been proposed as a biomarker for recurrence in prostate cancer patients to be treated with radical prostatectomy. A low tissue level of the metabolite citrate has additionally been connected to aggressive disease and recurrence in this patient group. However, for radiotherapy prostate cancer patients, few prognostic biomarkers have been suggested. The main aim of this study was to use an integrated tissue analysis to evaluate metabolites and expression of TOP2A and EZH2 as predictors for recurrence among radiotherapy patients.

[1]  R. Heeren,et al.  Spatial differentiation of metabolism in prostate cancer tissue by MALDI-TOF MSI , 2021, Cancer & metabolism.

[2]  Maria K. Andersen,et al.  Simultaneous Detection of Zinc and Its Pathway Metabolites Using MALDI MS Imaging of Prostate Tissue , 2020, Analytical chemistry.

[3]  F. Hamdy,et al.  Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy , 2019, The Prostate.

[4]  H. G. van der Poel,et al.  Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. , 2019, European urology.

[5]  Xin Lu,et al.  Metabolomics and transcriptomics profiles reveal the dysregulation of the tricarboxylic acid cycle and related mechanisms in prostate cancer , 2018, International journal of cancer.

[6]  Leslie R Euceda,et al.  Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy , 2017, British Journal of Cancer.

[7]  T. Bathen,et al.  SFRP4 gene expression is increased in aggressive prostate cancer , 2017, Scientific Reports.

[8]  F. Feng,et al.  TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup , 2017, Clinical Cancer Research.

[9]  J. Blenis,et al.  Adding Polyamine Metabolism to the mTORC1 Toolkit in Cell Growth and Cancer. , 2017, Developmental cell.

[10]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2017, European urology.

[11]  Alain Bergeron,et al.  Genomic hallmarks of localized, non-indolent prostate cancer , 2017, Nature.

[12]  T. Bathen,et al.  A novel non-canonical Wnt signature for prostate cancer aggressiveness , 2016, Oncotarget.

[13]  F. Feng,et al.  Biomarkers of Outcome in Patients With Localized Prostate Cancer Treated With Radiotherapy. , 2017, Seminars in radiation oncology.

[14]  David Gillatt,et al.  10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. , 2017, The New England journal of medicine.

[15]  W. Wong,et al.  Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers , 2016, PloS one.

[16]  Tao Huan,et al.  Metabolite Analysis and Histology on the Exact Same Tissue: Comprehensive Metabolomic Profiling and Metabolic Classification of Prostate Cancer , 2016, Scientific Reports.

[17]  D. Neal,et al.  Response of Degarelix treatment in human prostate cancer monitored by HR-MAS 1H NMR spectroscopy , 2016, Metabolomics.

[18]  T. Bathen,et al.  Presence of TMPRSS2-ERG is associated with alterations of the metabolic profile in human prostate cancer , 2016, Oncotarget.

[19]  Derya Yakar,et al.  Prostate MRSI predicts outcome in radical prostatectomy patients. , 2016, Magnetic resonance imaging.

[20]  T. Bathen,et al.  A Balanced Tissue Composition Reveals New Metabolic and Gene Expression Markers in Prostate Cancer , 2016, PloS one.

[21]  B. Delahunt,et al.  The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System , 2015, The American journal of surgical pathology.

[22]  E. Klein,et al.  The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer , 2015, Clinical Cancer Research.

[23]  Sarah H. Johnson,et al.  Topoisomerase 2 Alpha Cooperates with Androgen Receptor to Contribute to Prostate Cancer Progression , 2015, PloS one.

[24]  K. D. Sørensen,et al.  Expression profiling of prostate cancer tissue delineates genes associated with recurrence after prostatectomy , 2015, Scientific Reports.

[25]  G. Sauter,et al.  Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters. , 2015, Carcinogenesis.

[26]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[27]  G. Wilding,et al.  Expression of spermidine/spermine N1‐acetyl transferase (SSAT) in human prostate tissues is related to prostate cancer progression and metastasis , 2015, The Prostate.

[28]  S. Vowler,et al.  Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study , 2015, EBioMedicine.

[29]  Wei Zhang,et al.  Topoisomerase IIα in Chromosome Instability and Personalized Cancer Therapy , 2014, Oncogene.

[30]  G. Zhuang,et al.  TOP2Ahigh is the phenotype of recurrence and metastasis whereas TOP2Aneg cells represent cancer stem cells in prostate cancer , 2014, Oncotarget.

[31]  Esther G C Troost,et al.  Epigenetics in radiotherapy: where are we heading? , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[32]  Hans Garmo,et al.  Radical prostatectomy or watchful waiting in early prostate cancer. , 2014, The New England journal of medicine.

[33]  Anirban P. Mitra,et al.  Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy , 2013, PloS one.

[34]  T. Bathen,et al.  Spermine and Citrate as Metabolic Biomarkers for Assessing Prostate Cancer Aggressiveness , 2013, PloS one.

[35]  M. Kattan,et al.  Development and validation of a 32-gene prognostic index for prostate cancer progression , 2013, Proceedings of the National Academy of Sciences.

[36]  R. Rocha,et al.  Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer , 2013, Journal of Translational Medicine.

[37]  Shizhong Xu,et al.  An Accurate Prostate Cancer Prognosticator Using a Seven-Gene Signature Plus Gleason Score and Taking Cell Type Heterogeneity into Account , 2012, PloS one.

[38]  Timothy J Wilt,et al.  Radical prostatectomy versus observation for localized prostate cancer. , 2012, The New England journal of medicine.

[39]  J. Halgunset,et al.  Changes in Gene Transcription Underlying the Aberrant Citrate and Choline Metabolism in Human Prostate Cancer Samples , 2012, Clinical Cancer Research.

[40]  H. Gogas,et al.  HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy , 2012, Journal of Translational Medicine.

[41]  J. Halgunset,et al.  A new method to provide a fresh frozen prostate slice suitable for gene expression study and MR spectroscopy , 2011, The Prostate.

[42]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[43]  Zhenyu Jia,et al.  Diagnosis of prostate cancer using differentially expressed genes in stroma. , 2010, Cancer research.

[44]  Haojie Huang,et al.  Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer. , 2010, Endocrinology.

[45]  Zhenyu Jia,et al.  In silico estimates of tissue components in surgical samples based on expression profiling data. , 2010, Cancer research.

[46]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[47]  F Savorani,et al.  icoshift: A versatile tool for the rapid alignment of 1D NMR spectra. , 2010, Journal of magnetic resonance.

[48]  Leo L. Cheng,et al.  Retrospective analysis of prostate cancer recurrence potential with tissue metabolomic profiles , 2009, The Prostate.

[49]  M. Gerstein,et al.  Molecular sampling of prostate cancer: a dilemma for predicting disease progression , 2010, BMC Medical Genomics.

[50]  S. Fosså,et al.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial , 2009, The Lancet.

[51]  J. Hicks,et al.  Increased spermine oxidase expression in human prostate cancer and prostatic intraepithelial neoplasia tissues , 2008, The Prostate.

[52]  S. Cross,et al.  The polycomb group protein EZH2 regulates actin polymerization in human prostate cancer cells , 2008, The Prostate.

[53]  F. Hamdy,et al.  EZH2 promotes proliferation and invasiveness of prostate cancer cells , 2007, The Prostate.

[54]  J. O’Leary,et al.  Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival. , 2007, Cancer research.

[55]  E. Elkin,et al.  Decision Curve Analysis: A Novel Method for Evaluating Prediction Models , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[56]  Tapio Visakorpi,et al.  The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late‐stage prostate cancer , 2006, Genes, chromosomes & cancer.

[57]  P. Carroll,et al.  Quantitative analysis of prostate metabolites using 1H HR‐MAS spectroscopy , 2006, Magnetic resonance in medicine.

[58]  T. Golub,et al.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. , 2006, Cancer research.

[59]  H. Matsumoto,et al.  N1,N12-Diacetylspermine as a Sensitive and Specific Novel Marker for Early- and Late-Stage Colorectal and Breast Cancers , 2005, Clinical Cancer Research.

[60]  K. Camphausen,et al.  Enhanced Radiation-Induced Cell Killing and Prolongation of γH2AX Foci Expression by the Histone Deacetylase Inhibitor MS-275 , 2004, Cancer Research.

[61]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[62]  J Kurhanewicz,et al.  Time‐dependent effects of hormone‐deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging , 2001, Magnetic resonance in medicine.

[63]  Wei Li,et al.  DNA topoisomerase IIβ and neural development , 2000 .

[64]  A. Otte,et al.  Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation , 1999, Nature Genetics.

[65]  P. Narayan,et al.  Citrate in the diagnosis of prostate cancer , 1999, The Prostate.

[66]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[67]  Y. Oshika,et al.  P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.